<code id='ECC3E1A325'></code><style id='ECC3E1A325'></style>

<acronym id='ECC3E1A325'></acronym>

<center id='ECC3E1A325'><center id='ECC3E1A325'><tfoot id='ECC3E1A325'></tfoot></center><abbr id='ECC3E1A325'><dir id='ECC3E1A325'><tfoot id='ECC3E1A325'></tfoot><noframes id='ECC3E1A325'>

<optgroup id='ECC3E1A325'><strike id='ECC3E1A325'><sup id='ECC3E1A325'></sup></strike><code id='ECC3E1A325'></code></optgroup>

<b id='ECC3E1A325'><label id='ECC3E1A325'><select id='ECC3E1A325'><dt id='ECC3E1A325'><span id='ECC3E1A325'></span></dt></select></label></b><u id='ECC3E1A325'></u>

~~<i id='ECC3E1A325'><strike id='ECC3E1A325'><tt id='ECC3E1A325'><pre id='ECC3E1A325'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：focus 2025-10-01 04:29:18 Page View：839

Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT — Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

advertisement

The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT Summit: How researchers deal with rejection
Next article： Heart attack and stroke risk calculators need revising

comprehensive

DIEP, the 'gold standard' of breast reconstruction, is under threat

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Results on Novartis prostate cancer therapy could expand its use

Results on Novartis prostate cancer therapy could expand its use

TheNovartisboothatESMO2023inMadrid.AndrewJoseph/STATMADRID—ResultspresentedMondaycouldexpandtheuseof

DIEP, the 'gold standard' of breast reconstruction, is under threat

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

How to make AI work for medicine

AdobeAdvancementsinLLMssuchasChatGPTandGPT-4havegeneratedsubstantialexcitement.Manyseethesemodelsasa

read more